Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.67 |
| ▸ | SHBG | P04278 | 2/20 | 0.67 |
| ▸ | PGR | P06401 | 2/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.67 |
| ▸ | AR | P10275 | 2/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.67 |
| ▸ | SNCA | P37840 | 2/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30060206 | 1.00 | ESR1 (0.69) | ESR1ESR2HSD17B10LMNANR3C1 | |
| SCHEMBL4906263 | 1.00 | ESR1 (0.69) | ESR1ESR2HSD17B10LMNANR3C1 | |
| SCHEMBL18919494 | 1.00 | ESR1 (0.69) | ESR1ESR2HSD17B10LMNANR3C1 | |
| SCHEMBL22368047 | 1.00 | ESR1 (0.69) | ESR1ESR2HSD17B10LMNANR3C1 | |
| SCHEMBL4903481 | 1.00 | ESR1 (0.69) | ESR1ESR2HSD17B10LMNANR3C1 | |
| SCHEMBL29198797 | 1.00 | ESR1 (0.69) | ESR1ESR2HSD17B10LMNANR3C1 | |
| SCHEMBL18935788 | 1.00 | ESR1 (0.69) | ESR1ESR2HSD17B10LMNANR3C1 | |
| SCHEMBL10520331 | 0.90 | ESR1 (0.57) | ESR1ESR2HSD17B10LMNANR3C1 | |
| SCHEMBL11100027 | 0.89 | ESR1 (0.67) | ESR1ESR2HSD17B10LMNANR3C1 | |
| SCHEMBL11100019 | 0.89 | ESR1 (0.67) | ESR1ESR2HSD17B10LMNANR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| US-4013688-A | STEROIDS | THE UPJOHN COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293683-A1 | Hormone Replacement Therapy | ESR2, SHBG, ESRRG | ESR1 4/4885ESR2 1/4885HSD17B10 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.